title: Acebutolol: ten years of experience.
abstract: During 10 years of clinical use involving almost 3 million patient-years, acebutolol has become established as a remarkably safe and well-tolerated beta-blocking agent, effective in treating essential hypertension and cardiac arrhythmias. The existence of a long-lived active metabolite (diacetolol) confers a 24-hour duration of action, which permits effective use of a once-daily regimen, particularly for hypertension. Acebutolol has low lipid solubility and low protein binding; the former property reduces the risk of central side effects, and the latter means that displacement interactions with other drugs are unlikely. Because acebutolol and its metabolite normally have both renal and hepatic excretion pathways, an alternative pathway is available should either be compromised through disease. Acebutolol is cardioselective, and clinical use has borne out the low incidence of bronchospasm in patients with impaired lung function. The possession of intrinsic sympathomimetic activity (ISA) leads to only modest reductions in cardiac output, which in turn reduces the chance of excessive bradycardia and the likelihood of precipitating heart failure. A combination of selectivity and ISA may be responsible for the low incidence of tiredness and cold extremities observed with acebutolol compared with other beta blockers. The unique pharmacologic and pharmacokinetic profile of acebutolol confers several therapeutic advantages and may be responsible for the generally low level of side effects experienced in clinical use.
authors.forename: G
authors.initials: G
authors.lastname: De Bono
authors.forename: C M
authors.initials: CM
authors.lastname: Kaye
authors.forename: E
authors.initials: E
authors.lastname: Roland
authors.forename: A J
authors.initials: AJ
authors.lastname: Summers
mesh_terms: D000070:Acebutolol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000097:blood / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D000367:Age Factors; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001775:Blood Circulation / Q000187:drug effects; D001980:Bronchi / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D004347:Drug Interactions; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007674:Kidney Diseases / Q000097:blood; D007700:Kinetics; D008107:Liver Diseases / Q000097:blood; D013566:Sympathomimetics / Q000494:pharmacology
chemical_list: D000319:Adrenergic beta-Antagonists; D013566:Sympathomimetics; C025527:diacetolol; D000070:Acebutolol